<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219075</url>
  </required_header>
  <id_info>
    <org_study_id>1B-10-6</org_study_id>
    <secondary_id>NCI-2010-01847</secondary_id>
    <nct_id>NCT01219075</nct_id>
  </id_info>
  <brief_title>Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer</brief_title>
  <official_title>Soy Treatment for High-risk Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>California Breast Cancer Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use&#xD;
      of soy isoflavones supplements may prevent or treat early stage breast cancer. PURPOSE: This&#xD;
      clinical trial studies soy isoflavones supplementation in treating women at high risk for or&#xD;
      with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To assess whether magnetic resonance imaging (MRI) volume (equivalent&#xD;
      to 3-dimensional mammographic density) is reduced in high-risk women or those with invasive&#xD;
      breast cancer or DCIS who are supplemented daily with soy (5p mg total isoflavones as&#xD;
      aglycone) compared to placebo (microcrystalline cellulose) tablets for 1 year.II. To assess&#xD;
      whether cell proliferation and apoptosis, as measured by Ki67 and caspase 3 staining,&#xD;
      respectively, of breast epithelial cells is altered with soy treatment.SECONDARY OBJECTIVES:&#xD;
      I. To assess whether other intermediate molecular markers including estrogen receptor alpha&#xD;
      (ER alpha) and ER beta differ between women supplemented with soy vs placebo. OUTLINE:&#xD;
      Patients are randomized to 1 of 2 treatment arms.ARM I: Patients receive oral soy isoflavones&#xD;
      supplement once daily for12 months in the absence of disease progression.ARM II: Patients&#xD;
      receive oral placebo once daily for 12 months in the absence of disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2010</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with reduced MRI volume (MRIV)</measure>
    <time_frame>At completion of 12 months on the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of cells that stain positive for Ki67, caspase 3, ratio of Ki67/caspase, ER alpha and ER beta</measure>
    <time_frame>At completion of 12 months on the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>BRCA1 Mutation Carrier</condition>
  <condition>BRCA2 Mutation Carrier</condition>
  <condition>Ductal Breast Carcinoma in Situ</condition>
  <condition>Lobular Breast Carcinoma in Situ</condition>
  <condition>Stage IA Breast Cancer</condition>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral soy isoflavones supplement once daily for 12 months in the absence of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo once daily for 12 months in the absence of disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy isoflavones</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>NovaSoy</other_name>
    <other_name>soy phytoestrogens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>MRI</other_name>
    <other_name>NMR imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>mammography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women at high risk for breast cancer, defined as any of the following groups:&#xD;
&#xD;
          -  Five year Gail risk &gt; 1.7%&#xD;
&#xD;
          -  Known BRCA1/BRCA2 mutation carrier&#xD;
&#xD;
          -  Family history consistent with hereditary breast cancer&#xD;
&#xD;
          -  Prior biopsy exhibiting atypical hyperplasia or lobular carcinoma in situ (LCIS)&#xD;
&#xD;
          -  History of invasive breast cancer or ductal carcinoma in situ (DCIS) and have&#xD;
             completed standard therapy including tamoxifen/aromatase inhibitor or will not be&#xD;
             treated with tamoxifen/aromatase inhibitor&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic breast cancer&#xD;
&#xD;
          -  Undergoing treatment (chemotherapy, radiation, or SERMs)&#xD;
&#xD;
          -  Pregnancy or breast-feeding, or planning to become pregnant within one year prior to&#xD;
             study entry&#xD;
&#xD;
          -  Regular soy consumers (i.e., &lt; once per week of soy food, soy supplements or other&#xD;
             products)&#xD;
&#xD;
          -  Known food allergies such as to soy or nuts&#xD;
&#xD;
          -  Not willing to avoid soy foods/supplements during study period&#xD;
&#xD;
          -  Current users of exogenous hormones or oral contraceptive or planning to use exogenous&#xD;
             hormones during the duration of the study&#xD;
&#xD;
          -  Cannot stop taking aspirin or NSAIDs within a week of breast biopsy&#xD;
&#xD;
          -  Active participant in other ongoing trials&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phytoestrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

